We posted about $APLM on August 14, and we got a number wrong. The post said 1.1 million shares are available to trade. Our own data says the tradeable pool is roughly twice that, and correcting it changes the whole picture.
A reader replied with a good point: the small share count is the result of a 100:1 reverse split, and the private-round investors from Seed through Series C are heavily down. That is very likely true. But it leads somewhere different from where the thread was heading, because those investors are largely not holding this stock any more.
Here is what our data actually shows.
The correction, and why it matters more than the error
Our published float figure of 2,185,291 subtracts institutional holdings and nothing else, because our insider parse for this ticker came back empty. That is the exact trap we wrote about in the low float piece: a float is only as good as what you subtracted, and if the source will not tell you, the number is unverified.
So take the honest range. Somewhere between 2.0 and 2.19 million shares are tradeable, against 2,196,052 outstanding. Call it 91% to 99% of the company.
This is what refutes the thread's premise. If Seed through Series C investors were still sitting on large restricted blocks, the float would be far below the share count. It is not. There is no big locked-up pool waiting to be released, because there is no big locked-up pool at all. Institutions hold under half a percent.
The early investors are almost certainly deeply underwater, exactly as the reply said. They are also, on this evidence, mostly no longer here.
One thing worth separating, because it gets conflated constantly: a reverse split does not put anybody down. One hundred shares at eleven cents become one share at eleven dollars, and the position is worth the same that afternoon as it was that morning. What put those investors down was the collapse that made the split necessary in the first place. The split is the marker, not the cause.
The number that actually tells the story
It is not in the share count. It is in a press release from October 2025.
Apollomics reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.
Read that again slowly. The company was winding up. Not restructuring, not pivoting. Winding up is the process of closing a company and returning whatever is left to shareholders. That plan was reversed because $4.1 million arrived, and a new board and management team came with it.
The current board and officer names on file (Jan Chen-Huan, Chen Yi-Kuei, Tsai Hsien-Shu, Chen Hong-Jung, Chu Yi-An, Chen Hung-Wen, Lin Peter Kuan-How, Huang Ya-Chi) are consistent with a new investor group taking control rather than a continuation of the people who ran it before.
So the honest framing of $APLM today is not "a beaten-down biotech with trapped early investors." It is a company that was months from closing, was bought a reprieve for $4.1 million, and is now valued at about $51 million.
What moved it, in context
On August 14 $APLM closed at $23.40 against $17.37 the day before, up 34.7%. It did that on 47,753 shares.
That is genuinely heavy for this stock, which normally trades between about 1,300 and 45,000 shares a day. It is also about $1.05 million in total, and 2.2% of the float changing hands.
Both things are true at once, and holding them together is the whole skill. A 34.7% move on a million dollars is not a verdict from the market. It is what happens when a thin book meets a few orders. The same thinness works in reverse and on the same scale.
For completeness on the short side, since that is where these conversations usually go: short interest is 6,733 shares, which is 0.31% of float, at 1 day to cover, and it fell 32.9% from the prior period. The stock is also flagged as not shortable and not easy to borrow. There is no squeeze setup here on any of the four checks from the squeeze piece.
What we could not check, and why we are saying so
The questions worth asking next are all financing questions. A clinical-stage oncology company that needed $4.1 million to avoid closing does not have years of runway, and $4.1 million does not fund a global trial programme. So: what has been raised since, on what terms, what is registered for resale, and what is the cash position.
We could not answer any of that today, because our SEC access is returning 403 from every path we tried. Our filings list for $APLM came back empty and our dilution panel reads "none". Neither of those means there is nothing to find. They mean the fetch failed and the failure was swallowed into an empty result.
We would rather print that sentence than let an empty list imply a clean bill of health. A microcap that reversed a liquidation is close to the last company on the market where "no dilution signals" should be read as reassurance.
The same applies to the clinical picture. APL-101 (vebreltinib) is what the October release names, and beyond the name we are not going to characterise trial stage, endpoints or timing from memory. That belongs in the filings, and the filings are what we currently cannot read.
What we would check, in order, when access is back
- The cash position and the burn rate, from the most recent periodic report. Runway in months is the only number that matters for a company in this position.
- Everything raised since October 2025, and on what terms. Convertibles and warrants issued cheaply are supply that does not exist yet and will.
- Registration statements, which is where PIPE shares become sellable. That is the actual overhang question, and it is not answerable from a float number.
- Whether the new board has bought anything on the open market. Twelve months, zero open-market insider buys, two sells. Grants are not conviction. Purchases are.
- The clinical calendar, from the filings rather than from a press release.
None of that is a view on the stock. It is the list of things a person would need to know before having one, and today we can honestly answer only the ownership half of it.
If you want the method behind all of this, the rest of the series is the four numbers that decide a short squeeze, why almost nobody can source a float, how old a 13F already is, and what relative volume is actually dividing by.
We got the float wrong in a post. The correction is above, it is ours, and it is the reason we publish the denominator every time.